Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

被引：8

作者：

Fernandez-Sanchez, Mireya ^{[1
]}

Ribes-Artero, Hugo ^{[1
]}

Roma-Sanchez, Eva ^{[1
]}

Gomez-Portero, M. Rosa ^{[2
]}

Guerrero-Hurtado, Eduardo ^{[1
]}

Garcia-Pellicer, Javier ^{[1
]}

Poveda-Andres, Jose Luis ^{[1
]}

机构：

[1] Hosp Univ & Politecn La Fe, Pharm Serv, Valencia, Spain

[2] Hosp Univ & Politecn La Fe, Gynecol Serv, Valencia, Spain

来源：

BIRTH DEFECTS RESEARCH | 2021年 / 113卷 / 17期

关键词：

JAK inhibitors; pregnancy; psoriatic arthritis; teratogenic effects; teratogenicity; tofacitinib; JANUS KINASE INHIBITOR; RHEUMATOID-ARTHRITIS; ANTIRHEUMATIC DRUGS; PREGNANCY OUTCOMES;

D O I：

10.1002/bdr2.1942

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Introduction Preclinical studies with tofacitinib demonstrated teratogenic effects. Data about effects on human fetuses are limited and current recommendations are to immediately discontinue the treatment. Our purpose is to report a case of exposure to tofacitinib during the first trimester of pregnancy. Case Summary A 40-year-old woman with psoriatic arthritis became pregnant during the first month of treatment with tofacitinib. Tofacitinib was interrupted immediately, and parents were informed about the possible risks of teratogenicity. At the end of pregnancy, our patient gave birth to a healthy newborn. Conclusion All the available evidence of tofacitinib exposure during pregnancy in humans belongs to outcomes of unexpected pregnancies in the context of clinical trials and post-marketing cases. This case may contribute to enriching available data about teratogenic risks of tofacitinib exposure during pregnancy.

引用

页码：1275 / 1279

页数：5